Infection Related Endpoints in Subsequent Courses
| . | Filgrastim . | Placebo . | |
|---|---|---|---|
| Induction 2 | |||
| Neutropenia duration (days) | |||
| Median (range) | 10.0 (0-38) | 14.0 (0-43) | P = .015 |
| Fever incidence | 48/60 (80%) | 50/67 (75%) | P = .47 |
| Intravenous anti-infectives incidence | 46/60 (77%) | 47/67 (70%) | P = .41 |
| Consolidation 1 | |||
| Neutropenia duration (days) | |||
| Median (range) | 4.0 (0-46) | 11.0 (0-22) | P = .0001 |
| Fever incidence | 80/162 (49%) | 99/157 (63%) | P = .014 |
| Intravenous anti-infectives incidence | 71/162 (44%) | 85/157 (54%) | P = .08 |
| Consolidation 2 (DAV 2 + 5 + 5) | |||
| Neutropenia duration (days) | |||
| Median (range) | 5.0 (0-18) | 10.0 (0-22) | P = .0001 |
| Fever incidence | 28/60 (47%) | 33/58 (57%) | P = .27 |
| Intravenous anti-infectives incidence | 22/60 (37%) | 30/58 (52%) | P = .07 |
| Consolidation 2 (HD-Ara-C/DNR) | |||
| Neutropenia duration (days) | |||
| Median (range) | 13.0 (6-26) | 18.5 (12-42) | P = .001 |
| Fever incidence | 20/21 (95%) | 24/26 (92%) | P = .68 |
| Intravenous anti-infectives incidence | 19/21 (90%) | 24/26 (92%) | P = .82 |
| . | Filgrastim . | Placebo . | |
|---|---|---|---|
| Induction 2 | |||
| Neutropenia duration (days) | |||
| Median (range) | 10.0 (0-38) | 14.0 (0-43) | P = .015 |
| Fever incidence | 48/60 (80%) | 50/67 (75%) | P = .47 |
| Intravenous anti-infectives incidence | 46/60 (77%) | 47/67 (70%) | P = .41 |
| Consolidation 1 | |||
| Neutropenia duration (days) | |||
| Median (range) | 4.0 (0-46) | 11.0 (0-22) | P = .0001 |
| Fever incidence | 80/162 (49%) | 99/157 (63%) | P = .014 |
| Intravenous anti-infectives incidence | 71/162 (44%) | 85/157 (54%) | P = .08 |
| Consolidation 2 (DAV 2 + 5 + 5) | |||
| Neutropenia duration (days) | |||
| Median (range) | 5.0 (0-18) | 10.0 (0-22) | P = .0001 |
| Fever incidence | 28/60 (47%) | 33/58 (57%) | P = .27 |
| Intravenous anti-infectives incidence | 22/60 (37%) | 30/58 (52%) | P = .07 |
| Consolidation 2 (HD-Ara-C/DNR) | |||
| Neutropenia duration (days) | |||
| Median (range) | 13.0 (6-26) | 18.5 (12-42) | P = .001 |
| Fever incidence | 20/21 (95%) | 24/26 (92%) | P = .68 |
| Intravenous anti-infectives incidence | 19/21 (90%) | 24/26 (92%) | P = .82 |
Wilcoxon Rank Sum Test used for comparing durations and χ 2 test for comparing incidences.
Abbreviations: DAV: daunorubicin, cytosine-arabinoside, etoposide. HD-Ara-C/DNR: high-dose cytosine-arabinoside/daunorubicin.